Shao‐Chun Wang
- Oncology top 2%
- HER2/EGFR in Cancer Research 16
- Cancer Immunotherapy and Biomarkers 7
- Cancer Cells and Metastasis 7
- Inorganic Chemistry top 2%
- Cancer Research top 2%
- MicroRNA in disease regulation 8
- Molecular Biology top 2%
- Glycosylation and Glycoproteins Research 7
- DNA Repair Mechanisms 7
- Immunology top 5%
- Immunotherapy and Immune Responses 8
-
- Monoclonal and Polyclonal Antibodies Research 16
Shao‐Chun Wang
147 papers receiving 6.1k citations
Hit Papers
Peers
Comparison fields: 5 of 160
- Oncology 1.6k
- Inorganic Chemistry 772
- Cancer Research 812
- Molecular Biology 3.1k
- Immunology 609
Countries citing papers authored by Shao‐Chun Wang
This map shows the geographic impact of Shao‐Chun Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shao‐Chun Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shao‐Chun Wang more than expected).
Fields of papers citing papers by Shao‐Chun Wang
This network shows the impact of papers produced by Shao‐Chun Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shao‐Chun Wang. The network helps show where Shao‐Chun Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shao‐Chun Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2022 | 11 | |
| 3 | 2022 | 3 | |
| 4 | 2022 | 5 | |
| 5 | 2022 | 21 | |
| 6 | 2022 | 13 | |
| 7 | 2021 | 1 | |
| 8 | 2021 | 24 | |
| 9 | Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease | 2020 | 66 |
| 10 | 2020 | 42 | |
| 11 | 2019 | 57 | |
| 12 | 2019 | 10 | |
| 13 | 2019 | 282 | |
| 14 | 2017 | 333 | |
| 15 | 2017 | 1 | |
| 16 | 2012 | 88 | |
| 17 | 2011 | 76 | |
| 18 | Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016). | 2011 | 16 |
| 19 | 2008 | 65 | |
| 20 | 2004 | 241 |
About Shao‐Chun Wang
Shao‐Chun Wang is a scholar working on Oncology, Cancer Research and Immunology and Allergy, having authored 149 papers that have together received 6.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (16 papers), Monoclonal and Polyclonal Antibodies Research (16 papers), MicroRNA in disease regulation (8 papers), Immunotherapy and Immune Responses (8 papers), Cancer Immunotherapy and Biomarkers (7 papers), Glycosylation and Glycoproteins Research (7 papers), Cancer Cells and Metastasis (7 papers) and DNA Repair Mechanisms (7 papers). The work is most often cited by research in Oncology (1.6k citations), Inorganic Chemistry (772 citations) and Cancer Research (812 citations). Shao‐Chun Wang has collaborated with scholars based in United States, Taiwan and China. Frequent co-authors include Mien‐Chie Hung, Fa‐Kuen Shieh, Kevin C.‐W. Wu, Lien‐Yang Chou, Joseph V. Morabito, Chia‐Kuang Tsung, Peter M. Fischer, Weiya Xia, Pan Hu and Eing‐Mei Tsai. Their work appears in journals such as Scientific Reports, American Journal of Physiology-Legacy Content, Oncogene, Biochemistry and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.